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AbstrAct
Objective Quantify the efficacy of strategies to prevent 
contrast-induced acute kidney injury (CI-AKI) in high-risk 
patients undergoing coronary angiography (CAG) with or 
without percutaneous coronary intervention (PCI).
Background CI-AKI remains a common problem. The 
renoprotective efficacy of existing pharmacological agents 
remains uncertain in high-risk populations.
Methods Systematic review and meta-analysis of 
randomised controlled trials (RCTs) to compare different 
strategies versus hydration in patients with chronic kidney 
disease (CKD) undergoing CAG±PCI. Primary outcome was 
incident CI-AKI. Fixed-effects meta-analyses estimated 
ORs, 95% CIs and heterogeneity.
Results Forty-eight RCTs were included. Seven 
pharmacological strategies were evaluated by multiple 
RCTs and 10 by one RCT each. These had varying 
risk of bias; >25% of trials were at high risk of 
performance bias. Five strategies significantly reduced 
the odds of CI-AKI: N-acetylcysteine (NAC) (27 trials, 
5694 participants; OR=0.77, 95% CI 0.65 to 0.91, 
p=0.002, I2=36%), ascorbic acid (four trials, 759 
participants; OR=0.59, 95% CI 0.39 to 0.89, p=0.01, 
I2=0%), statin (two trials, 3234 participants; OR=0.59, 
95% CI 0.39 to 0.89, p=0.75, I2=0%), trimetazidine 
(two trials, 214 participants; OR=0.27, 95% CI 0.10 
to 0.71, p=0.01, I2=0%) and nicorandil (two trials, 
389 participants; OR=0.47, 95% CI 0.23 to 0.94, 
p=0.03, I2=52%). Theophylline had a similar, but non-
significant, effect. A subgroup analysis found that the 
benefit of NAC was highest in patients requiring a 
high-contrast dose.
Conclusions Several drugs are renoprotective in patients 
with CKD undergoing CAG±PCI. The evidence is strongest 
for NAC. We recommend that NAC should be used when a 
high dose of contrast is anticipated.
Trial registration number PROSPERO registration 
CRD42014014704.
Open Science Framework link: https:// osf. io/ vxg7d/? view_ 
only= 62ba d040 4b18 405a bd39 ff2e ad2575a8
InTROduCTIOn
Contrast-induced acute kidney injury 
(CI-AKI) is common and an important prog-
nostic factor in patients undergoing coronary 
angiography (CAG) for diagnosis or percu-
taneous coronary intervention (PCI).1 2 It is 
the third most common cause of hospital-ac-
quired AKI after the AKI induced by cardiac 
surgery and hypotension.3 Expansion in 
the use of iodinated contrast media for 
CAG±PCI, together with an ageing patient 
Key questions
What is already known about this subject?
 ► Contrast-induced acute kidney injury (CI-AKI) is a 
common and important complication of coronary 
angiography (CAG). Numerous pharmacological 
strategies have been proposed as renoprotective. 
However, at present, intravenous hydration is the 
only universally accepted practice for those patients 
deemed at high risk of developing CI-AKI.
What does this study add?
 ► While previous systematic reviews have assessed 
efficacy of multiple pharmacological strategies in 
a general population, we look specifically at those 
with established chronic kidney disease (CKD) who 
are at high risk of developing CI-AKI.
How might this impact on clinical practice?
 ► Several strategies were found to be renoprotec-
tive in our meta-analysis; renoprotection with 
N-acetylcysteine (NAC) was most certain. Given 
the results of our meta-analysis, the good safe-
ty profile, availability and familiarity of healthcare 
professionals with NAC, we recommend its use for 
the prevention of CI-AKI in patients with CKD where 
high-contrast doses are anticipated.
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population, means that the incidence of CI-AKI is likely 
to increase.
CI-AKI is currently defined as: an increase in serum 
creatinine ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours, 
or ≥1.5 times the baseline value, or urine output <0.5 
mL/kg/hour for over six consecutive hours (kidney 
disease improving global outcomes [KDIGO] interna-
tional guideline4). However, CI-AKI (or contrast-induced 
nephropathy) was historically defined as an increase in 
serum creatinine ≥0.5 mg/dL (≥44 µmol/L) or ≥25% 
from baseline within 72 hours of administering contrast 
medium.5
The incidence of CI-AKI in low-risk patients is only 3% 
but can be >30% in those at high risk of developing AKI.6 7 
Risk factors for the development of CI-AKI include pre-ex-
isting renal impairment, diabetes mellitus, advanced age, 
congestive heart failure and the concurrent adminis-
tration of nephrotoxic drugs. CI-AKI in these high-risk 
patients is associated with a need for dialysis, prolonged 
hospital stay, increased costs and mortality.8
Currently recommended renoprotective strategies are 
intravenous hydration in high-risk patients using 0.9% 
sodium chloride or isotonic sodium bicarbonate.4 These 
strategies reduce the risk of CI-AKI compared with no 
intervention.9 10 The efficacy of pharmacological inter-
ventions such as N-acetylcysteine (NAC) compared with 
hydration alone is uncertain especially in patients at 
high-risk of developing CI-AKI; international guidelines 
recommend not using NAC for renoprotection in such 
patients due to a lack of evidence.11
Given the risk of CI-AKI in high-risk patients, it is 
important to estimate the efficacy of currently used phar-
macological agents to prevent CI-AKI. Therefore, we 
undertook a systematic review and meta-analysis of all 
randomised controlled clinical trials (RCTs) of pharma-
cological agents to prevent CI-AKI in patients with pre-ex-
isting chronic kidney disease (CKD).
MeTHOds
A protocol was written in advance describing the objec-
tives, criteria for study selection, clinical outcomes, the 
method for assessing risk of bias and statistical methods 
(online supplementary efile 1). The review adhered to 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses guidelines.12
study identification
Two investigators (AJS and FF) identified all relevant 
published RCTs evaluating the renoprotective effect of 
pharmacological agents in adult patients undergoing 
CAG±PCI. AJS searched Ovid MEDLINE and  Clinical-
Trials. gov from 1999 to 10 March 2018 using the search 
strategy agreed by the two authors and described in 
online supplementary etable 1. This date range (18 years) 
was chosen to capture modern practice. Bibliographies of 
included studies and recent review articles were checked 
by AJS and FF for additional relevant articles.
study selection
AJS and FF independently assessed trials for eligibility. 
Disagreements were resolved by consensus. Inclusion 
criteria were: (1) RCT design, AND (2) patients with 
CKD, AND (3) undergoing CAG±PCI, AND (4) control 
group treated by hydration with normal saline, AND (5) 
AKI defined as an outcome. Non-English and non-human 
were exclusion criteria. If there were multiple publica-
tions from an RCT, all were reviewed for data extraction 
and to clarify the methods or the characteristics of the 
population studied; the maximum reported sample size 
was recorded.
Outcome
The primary outcome was CI-AKI. Definitions of CI-AKI 
varied and were documented. If an RCT reported results 
for multiple CI-AKI definitions, data for the most sensi-
tive definition (yielding the highest CI-AKI incidence) 
were extracted. Secondary outcomes considered were 
need for haemodialysis, major adverse cardiac-related 
events (MACEs), admission to intensive therapy units 
(ITU) and death.
Assessment of risk of bias
Included trials were appraised using the Cochrane risk of 
bias tool.13 AJS and FF assessed each outcome of interest 
to the review as being at low, high or unclear risk of bias 
in each of five domains: sequence generation; allocation 
concealment; blinding of participants, personnel and 
outcome assessors; incomplete outcome data; and selec-
tive outcome reporting.
data extraction
Data extraction was done independently by AJS and FF 
and included author, year of publication, country of 
origin, study design, sample size, inclusion and exclusion 
criteria, definition of CKD and CI-AKI and study results. 
Discrepancies were addressed by joint re-evaluation of 
the original article.
statistical analysis
Pooled ORs and 95% CIs were estimated using fixed-ef-
fects meta-analyses. The robustness of results was inves-
tigated by comparing the results of fixed-effects and 
random-effects meta-analyses. We tested for and quanti-
fied heterogeneity using the Q and I2 statistics, respec-
tively.14 Small study effects were assessed by visual inspec-
tion of funnel plots.
We conducted stratified analyses of trials evaluating 
NAC to investigate whether the treatment effect varied 
according to trial characteristics relating to eligibility 
criteria for the trial (diabetic status and baseline serum 
creatinine) and the ways in which NAC and the control 
treatment were administered (NAC dose and oral vs 
intravenous administration). For studies evaluating NAC, 
we also assessed the risk of small study bias by Harbord’s 
modified test for small-study effects. All analyses were 
carried out using RevMan 5.3 (Copenhagen: The Nordic 
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Figure 1 Flow diagram of search strategy. CAG, coronary angiography; CKD, chronic kidney disease; RCT, randomised 
controlled trial.
Cochrane Centre, The Cochrane Collaboration, 2014) 
and Stata 10.0.
ResulTs
Trial characteristics
Forty-eight eligible RCTs15–62 enrolled 14 709 patients with 
CKD undergoing CAG±PCI. Figure 1 shows the results 
of the search and the number of citations at different 
stages of the selection process. The list of papers that 
were excluded and reason for exclusion is outlined in 
online supplementary etable 2. Seven interventions were 
evaluated in multiple RCTs (NAC, sodium bicarbonate, 
theophylline, statin, ascorbic acid, trimetazidine and 
nicorandil). Nine RCTs compared multiple interventions 
against a single control group. A further seven single 
interventions and three intervention combinations were 
evaluated by single trials: alpha-lipoic acid, anisodamine, 
dopamine, fenoldopam, zinc, glutathione, high-dose 
hydration, NAC+ascorbic acid, NAC+high dose hydration 
and NAC+theophylline. Included trials are described in 
online supplementary etable 3.
RCT populations varied according to whether partic-
ipants had CAG only or CAG+PCI and how CKD was 
defined. The definition of CI-AKI also varied (table 1); 
an absolute increase in serum creatinine (sCr) of ≥0.5 
mg/dL or a relative increase ≥25% within 48 hours was 
used most often (20 studies). One trial used estimated 
glomerular filtration rate to define CI-AKI. The dose 
of interventional agent administered and the route 
of administration also varied. CI-AKI incidence in the 
control groups for different definitions of CI-AKI was very 
variable (table 1). For the most commonly used CI-AKI 
definition, the median incidence of CI-AKI in the control 
group was 10.9% with an interquartile interval ranging 
from 5.9% to 14.3%. Across all interventions, 26 RCTs 
reported incident dialysis, eight trials reported incident 
MACE and 13 RCTs reported death. None reported find-
ings for intensive care unit admission.
The treatment effects for interventions evaluated in 
single trials were based on sample sizes <500 and most 
demonstrated no statistically significant benefit. A 
single-blind trial in 260 patients with diabetes evaluated 
 o
n
 5 M
arch 2019 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000864 on 25 January 2019. Downloaded from
 
Open Heart
4 Sharp AJ, et al. Open Heart 2019;6:e000864. doi:10.1136/openhrt-2018-000864
Table 1 Definition of contrast-induced acute kidney injury (CI-AKI) and incidence in the control group
Definition of CI-AKI
# of 
studies Incidence of CI-AKI (%) in the control group
Increase of sCr ≥0.5 mg/dL or reduction in eGFR ≥25% within 48 
hours
1 13.3%21
Increase of sCr ≥0.5 mg/dL or increase sCr ≥25% within 48 hours 20 0%,39 2.7%,33 3.4%,44 5%,30 5.4%,42 6.3%,36 6.4%,28 6.6%,46 6.9%,47 
10.0%,57 11.8%,54 13%,3413.6%,55 14%,16 14.3%,15 14.3%,56 16.6%,43 
23.8%,18 25%,27 44.8%19
Increase of sCr ≥0.5 mg/dL or increase sCr ≥25% within 72 hours 4 3.9%,45 12.5%,35 20.3%,52 20%,59 17.5%61
Increase of sCr ≥0.5 mg/dL or increase sCr ≥25% within 120 
hours
2 14%,50 20%,41 8.4%62
Increase of sCr ≥0.5 mg/dL or increase sCr ≥25% within 192 
hours
1 20.7%32
Increase of sCr ≥0.5 mg/dL or increase sCr ≥25% no timeframe. 1 16%60
Increase of sCr ≥0.5 mg/dL within 24 hours 1 5.8%29
Increase of sCr ≥0.5 mg/dL within 48 hours 9 6.0%,37 6.9%,53 8%,22 8%,23 12%–15.3%,48 20%,38 22.0%,20 24.6%31
Increase of sCr ≥0.5 mg/dL within 72 hours 1 32.1%49
Increase sCr ≥25% within 48 hours 1 12%24
Increase sCr ≥25% within 72 hours 2 22.2%,26 32%25
Increase sCr ≥25% within 96 hours 2 7.3%,40 21%,17
Increase sCr ≥25% no timeframe 1 30%51
Increase of sCr ≥44.2 µmol/L within 48 hours 1 10.1%58
eGFR, estimated glomerular filtration rate; sCr, serum creatinine.
Figure 2 Methodological quality graph – authors’ judgement on risk of bias associated with each methodological quality item 
presented as a percentage across all included studies.
anisodamine versus hydration with saline and showed 
a statistically significant reduction in the incidence of 
CI-AKI; OR for CI-AKI=0.43, 95% CI 0.21 to 0.88, p=0.02. 
Three trials of theophylline, two trials of trimetazidine 
and two trials of nicorandil also randomised <500 patients. 
However, the trials of trimetazidine and nicorandil did 
show a statistically significant reduction in incidence of 
CI-AKI (trimetazidine OR for CI-AKI=0.27, 95% CI 0.10 
to 0.71, p=0.01; nicorandil OR for CI-AKI 0.47, 95% CI 
0.23 to 0.94, p=0.03). The findings for these interventions 
are not considered further because of the low power of 
these RCTs.
Risk of bias
Figure 2 shows the risk of bias assessment for all RCTs. 
Approximately 50% of RCTs were judged to be at an 
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unclear risk of bias with respect to random sequence 
generation and allocation concealment due to inad-
equate reporting. Several RCTs were at high risk of 
performance bias; >25% failed to blind participants 
and personnel. The majority did not clearly report that 
outcome assessors were blinded and 40% had inadequate 
or unclear documentation of patients lost to follow-up.
Seven registered RCTs were identified through our 
search strategy that are not included in the metanalysis. 
Three were terminated before completion: one because 
the patient pathway became infeasible due to pressure for 
short hospital stays (NCT01786824); one because the drug 
became unavailable (NCT01071993); and one because it 
was not reaching its recruitment goal (NCT00494637). 
Data for these RCTs were not available. Three other RCTs 
(NCT01690832, NCT00424320 and NCT01871792) were 
described as status ‘unknown’; a PubMed search for the 
lead investigator did not identify any relevant publication 
of RCT results. One trial (NCT00531765) investigating 
sodium bicarbonate compared with saline appeared to 
have been completed in May 2010 but no publication of 
the results was found.
The funnel plots in esupplement online supplemen-
tary efigures 1–5 show graphs for all studies (all interven-
tions) and for NAC studies only. The distribution of the 
studies appears balanced suggesting a low risk of small 
study bias.
n-acetylcysteine
Twenty-seven trials (n=5694; sample sizes ranged from 
14 to 2482) assessed NAC with hydration compared with 
saline hydration alone with respect to the risk of CI-AKI 
(online supplementary etable 3). The NAC dose varied 
between 500 mg and 12 000 mg. Three trials administered 
NAC intravenously and 24 trials administered NAC orally. 
Eleven trials used 0.45% hydration and 16 used 0.90% 
hydration. Most trials identified incident CI-AKI for up to 
48 hours after the intervention but seven did so for longer. 
Overall, using a fixed-effects analysis, NAC resulted in a 
23% reduction in the odds of CI-AKI (OR=0.77, 95% CI 
0.65 to 0.91, p=0.002) with modest between-trial hetero-
geneity (I2=36%) (figure 3) and no evidence of bias due 
to small study effects (Harbord’s modified test for small 
study effects p=0.103; funnel plot (online supplemen-
tary efigure 5)). Results of a random-effects analysis were 
similar (OR=0.70, 95% CI 0.54 to 0.92, p=0.01).
Bicarbonate
Nine trials (n=3766; sample sizes ranged from 72 to 2498) 
evaluated hydration with sodium bicarbonate compared 
with normal saline. Sodium bicarbonate was infused in all 
but one trial; doses ranged from 12 mL/kg of 154 mEq/L 
to 1.5 mL/kg of 154 mEq/L sodium bicarbonate. Using a 
fixed-effects analysis, hydration with bicarbonate did not 
significantly reduce the odds of CI-AKI (OR=0.89, 95% 
CI 0.71 to 1.12, p=0.31) with some evidence of hetero-
geneity (I2=46%) (figure 3). Results of a random-effects 
analysis showed a similar trend (OR=0.72, 95% CI 0.45 to 
1.15, p=0.17).
Ascorbic acid
Four trials (n=759; sample sizes ranged from 81 to 231) 
evaluated ascorbic acid compared with normal saline. 
Doses ranged from 7 g oral to 500 mg intravenously. One 
trial investigated the occurrence of CI-AKI up to 120 hours 
following the intervention. Overall, using a fixed-effects 
analysis, ascorbic acid resulted in a 41% reduction in the 
odds of developing CI-AKI (OR=0.59, 95% CI 0.39 to 
0.89, p=0.01) with no heterogeneity (I2=0%) (figure 3). 
Results of a random-effects analysis were identical.
statin
Two trials (n=3234) evaluated statin compared with 
hydration with normal saline, with doses of 160 mg of 
simvastatin (n=236) and 50 mg rosuvastatin (n=2998). 
Overall, using a fixed-effects analysis, statin resulted in a 
41% reduction in odds of developing CI-AKI (OR=0.59, 
95% CI 0.39 to 0.89, p=0.75) (figure 3). Results of a 
random-effects analysis were identical.
secondary outcomes
The prespecified secondary outcomes were not reported 
across the majority of trials. Therefore, analyses were 
underpowered to detect a clinically important effect.
Pooled estimates for need for dialysis showed no signif-
icant reductions with NAC (15 RCTs, n=4277, OR=0.95, 
95% CI 0.52 to 1.76), bicarbonate (7 RCTs, n=3522, 
OR=0.99, 95% CI 0.51 to 1.93) or statins (2 RCTs, 1745 
pts, OR=0.33, 95% CI 0.01 to 8.13) compared with saline 
hydration. Nevertheless, all effect estimates were consis-
tent with the benefits shown for CI-AKI (online supple-
mentary efigure 2).
The pooled estimate effect of NAC compared with saline 
hydration on MACE showed no significant reduction in 
risk (4 RCTs, n=3007 patients, OR=1.16, 95% CI 0.90 to 
1.50; online supplementary efigure 3). Most trials did not 
report MACE. Pooled estimates for mortality were similarly 
imprecise for NAC (8 RCTs, n=3808, OR=1.29, 95% CI 0.87 
to 1.91) and bicarbonate (3 RCTs, n=2943, OR=1.21, 95% 
CI 0.76 to 1.93; Online supplementary efigure 4).
stratified analyses
Analyses of RCTs evaluating NAC, by diabetic status, type 
of intervention, contrast dose, baseline serum creatinine, 
NAC dose, route of administration, date of publication 
and risk of bias, are summarised in table 2. Studies were 
considered at low risk of bias if they demonstrated alloca-
tion concealment and either blinding of participants and 
personnel or outcome assessment.
The benefit of NAC in preventing CI-AKI appeared 
to be greater in trials where a larger average volume of 
contrast was used (average contrast volume >125 mL, 
OR=0.45, 95% CI 0.32 to 0.64, I2=28% vs average contrast 
volume <125 mL OR=0.89, 95% CI 0.74 to 1.08, I2=13%). 
All trials used either low or iso-osmolar contrast. The 
benefit of NAC was also more evident in trials recruiting 
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Figure 3 Forest plot of drugs (experimental) versus hydration with saline (control) in incidence of contrast-induced acute 
kidney injury.
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Table 2 Subgroup analysis of N-acetylcysteine (NAC) trials
Characteristic Stratum N/n OR 95% CI I2
Diabetic status Diabetic 1/87 0.75 0.21 to 2.67 n/a
Non-diabetic 26/5607 0.77 0.65 to 0.91 39
Intervention CAG 14/3996 0.80 0.65 to 0.99 50
CAG/PCI 13/1698 0.72 0.55 to 0.93 16
Contrast dose* <125 mL 13/4300 0.89 0.74 to 1.08 13
>125 mL 13/1344 0.45 0.32 to 0.64 28
Renal function* sCr ≥1.1 11/1640 0.76 0.57 to 1.02 0
sCr ≥1.4 13/980 0.46 0.32 to 0.65 46
NAC dose* <2400 mg 6/1214 0.74 0.54 to 1.00 53
=2400 mg 13/1349 0.69 0.49 to 0.98 32
>2400 mg 7/3071 0.87 0.68 to 1.11 31
NAC route Oral 23/4701 0.77 0.64 to 0.94 34
Intravenous 4/993 0.75 0.54 to 1.04 60
Date 1999–2008 20/2396 0.62 0.48 to 0.80 41
2009–present 7/3298 0.92 0.73 to 1.13 0
Risk of bias Low risk 10/3975 0.82 0.67 to 1.00 52
High risk 17/1719 0.67 0.49 to 0.90 26
*The sum of the trials across strata for contrast dose do not sum 27 because one trial did not report average contrast dose. Likewise for 
renal function, three trials did not describe baseline sCr adequately and were excluded. Likewise for NAC, dose one trial based dose on 
patient weight and was excluded.
CAG, coronary angiography; N, number of trials; PCI, percutaneous coronary intervention; n, total number of participants; sCr, serum 
creatinine.
patients with severe CKD (baseline sCr ≥1.4 mg/dL; 
OR=0.46, 95% CI 0.32 to 0.65, I2=46%) compared with 
less severe or moderately severe CKD (baseline sCr ≥1.1 
mg/dL; OR 0.76, 95% CI 0.57 to 1.02, I2=0%; interac-
tion chi2=4.61, df=1, p=0.032). The benefit of NAC was 
not evident in trials conducted after 2009 (before 2009, 
OR=0.62 (95% CI 0.48 to 0.80); after 2009 OR=0.92 (95% 
CI 0.73 to 1.13)).
dIsCussIOn
Main findings
Our review has three main findings. First, several agents 
significantly reduce the incidence of CI-AKI in high-risk 
patients undergoing CAG±PCI. The evidence is most 
certain for NAC; efficacy was estimated with excellent 
precision (27 RCTs recruiting >5000 patients) with only 
moderate heterogeneity (I2=36%). Second, the benefit 
of NAC is most evident in those receiving higher contrast 
doses (>125 mL of iso or low osmolar contrast). Finally, 
NAC appears to have greater efficacy in patients with more 
severe CKD. The benefits of other agents found to be signif-
icantly renoprotective were larger, ranging from OR=0.27 
(trimetadzine) to 0.59 (statin and ascorbic acid) but were 
estimated less precisely, since they were based on few trials 
(2–4) or included fewer participants (214–3234).
strengths and limitations
We conducted the review according to a prespecified 
protocol, used a comprehensive search strategy, assessed 
the risk of bias in trials using a recommended tool and 
explored a range of trial characteristics that might 
explain heterogeneity of trial estimates.
It could be argued that the overall effect of NAC might 
arise from an epoch effect, that is, only be apparent in 
earlier trials, particularly in the light of the results of the 
prevention of serious adverse events following angiog-
raphy (PRESERVE) trial.62 This international multicentre 
factorial trial is the only trial to have reported in the last 
5 years. It randomised over 5000 patients at high risk for 
CI-AKI to receive intravenous bicarb or 0.9% saline and 
oral NAC or placebo. The trial was stopped early due 
to absence of effect after 67% of the target recruitment 
was completed. The PRESERVE trial contributes 30% of 
the total weight in the NAC meta-analysis and inevitably 
dominates the estimate for trials reporting after 2009.
We carried out additional subgroup analyses, varying 
the cutpoint for classifying included RCTs into older and 
more recent subgroups; we compared effect estimates 
for older and more recent subgroups and inspected the 
risk of bias of included trials as a function of time (see 
online supplementary etable 4 and online supplemen-
tary efigure 6). These analyses show that: (A) the stratum 
specific estimates are stable over the period since 2004; 
(B) there is no evidence that older RCTs had a higher risk 
of bias; and (C) the treatment effect was larger for earlier 
studies than later studies.
We argue that a change in practice between time periods 
is the likeliest explanation (given that more recent trials 
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were not, on average, ‘better’). For example, improved 
techniques leading to a lower dose of contrast being 
required (online supplementary etable 5 details trial date 
arranged by average contrast dose used). However, NAC 
remains a sensible and potentially beneficial intervention 
in cases where greater doses of contrast are likely to be 
required, for example, in patients with known difficult 
access or chronic total occlusion procedures.
There are some other limitations. RCTs varied in their 
eligibility criteria, notably the severity of CKD that quali-
fied patients as eligible, definitions of CI-AKI used, dose 
and route of administration of the drug being evaluated. 
We investigated the effects of RCT characteristics for 
RCTs of NAC but, except for the comparison patients 
with severe versus moderately severe and severe CKD, 
these analyses had low power. They were also potentially 
confounded by other RCT characteristics, for example, 
country or dates when the trial was conducted.
We had not prespecified any hypothesis about modi-
fication of the relative treatment effect by the severity 
of CI-AKI events. Although RCTs used different CI-AKI 
definitions, we did not carry out a subgroup analysis by 
CI-AKI severity to quantify the interaction because of the 
diversity of definitions (table 1). Future RCTs will likely 
use a consistent CI-AKI definition.4
Some trials compared multiple interventions against 
a common control group. However, multiple estimates 
from a single trial were never included in the same 
meta-analyses, avoiding the need to take into account the 
dependency between two or more estimates. We iden-
tified seven trials for which we were unable to find any 
data, which could have caused publication bias.
Cochrane recommends that review authors should 
not include search terms describing relevant outcomes 
because this may lead review authors to overlook trials 
that are at risk of selective outcome reporting.63 We 
believe we avoided this risk, despite specifying CI-AKI 
in the search strategy, because of the specific nature of 
the research question; it is hard to conceive of an RCT 
designed to evaluate an intervention to reduce incident 
CI-AKI not subsequently reporting this effect.
Findings in relation to existing literature
Current guidelines recommend several strategies to 
prevent CI-AKI.4 Non-pharmacological strategies include 
using the lowest possible dose of contrast medium and 
using iso-osmolar or low-osmolar iodinated contrast 
medium in patients at risk of CI-AKI. The main pharma-
cological intervention is intravenous volume expansion 
with isotonic sodium chloride in patients at high-risk of 
CI-AKI.4 Current guidelines do not agree about the use 
of NAC for renoprotection. The international KDIGO 
guidelines recommend using oral NAC together with 
intravenous isotonic crystalloids for the prevention of 
CI-AKI.4 However, this recommendation is graded as level 
2D, indicating that the supporting evidence is considered 
very low quality. The recent UK guidelines recommend 
against using NAC as there is no convincing evidence.64
The current uncertainty about the use of NAC arises 
from 11 recently published systematic reviews.65–76 
Seven of these reviews found NAC to be renoprotective. 
However, marked heterogeneity and the risk of publica-
tion bias caused their authors to question the validity of 
these findings. The heterogeneity of effect observed in 
the reviews may have arisen because the reviews included 
RCTs that recruited both low-risk and high-risk patients. 
Our meta-analysis of solely high-risk patients demon-
strated only modest heterogeneity. Even among the high-
risk patients that were the focus of this review, we found 
evidence that the benefit of NAC is greatest in patients 
with severe CKD.
Two systematic reviews published over 10 years 
ago restricted their analyses to patients with baseline 
CKD.77 78 Both reviews found a renoprotective effect 
of NAC in patients with pre-existing CKD under-
going procedures requiring intravenous radiocontrast 
medium. However, they examined heterogenous popu-
lations with participants in included studies under-
going CT or CAG.
The beneficial effects of NAC, sodium bicarbonate, 
ascorbic acid and statin are scientifically plausible. Gener-
ation of reactive oxygen species is central to the patho-
physiology of CI-AKI.79 Patients with CKD have defective 
antioxidant systems and increased oxidative stress associ-
ated with inflammation and endothelial dysfunction.80 81 
Administration of antioxidants such as NAC would, there-
fore, be expected to replenish antioxidant stores and 
remove oxygen free radicals, reducing contrast induced 
inflammation and renal cell death.
We recommend using NAC for the prevention of CI-AKI 
in patients with CKD who are expected to require high 
doses of contrast. We recommend NAC rather than another 
agent for the following reasons: (1) the effect estimate has 
good precision and is derived from many studies, (2) NAC 
is cheap and easily available, (3) has a good safety profile 
and (4) health professionals are familiar in its adminis-
tration. We recommend using a NAC dose of 2400 mg as 
this was found efficacious in the largest number of trials 
and had only minor heterogeneity. Both intravenous and 
oral routes of administration were equally effective and we 
therefore recommend that the route of administration be 
tailored to the clinical scenario.
COnClusIOn
In conclusion, we have demonstrated that NAC, sodium 
bicarbonate, ascorbic acid and statins are renoprotective 
in patients with CKD undergoing CAG/PCI. Evidence 
is strongest for NAC in patients requiring high-contrast 
doses. The trials we included in our review tended to be 
small and most were at risk of bias in at least one domain. 
Nevertheless, the magnitude, consistency and precision 
of the observed effect is unlikely to be explained by bias. 
We recommend that guidelines concerning CI-AKI be 
amended to reflect this evidence.
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